Overview

The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on bottom-up and top-down attentional control to socio-emotional stimuli by combining a validated saccade/antisaccade eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.

Eligibility

Inclusion Criteria:

        Healthy subjects who volunteer to participate and are able to fully understand and agree
        with this study by written informed consent.
        Normal or corrected-normal version
        Exclusion Criteria:
          -  History of neuropsychiatric diseases.
          -  History of cardiac disease, including arrhythmias, aortic stenosis, or congestive
             heart failure; history of syncope or unexplained loss of consciousness.
          -  History of hepatic diseases, including cholestasis, biliary obstructive disease, or
             severe liver dysfunction.
          -  History of renal diseases, including renal stones or renal failure.
          -  History of hyponatremia(Serum sodium <135mmol/L) or hyperkalemia (Serum
             potassium>5.5mmol/L); history of diabetes mellitus or diabetes insipidus
          -  Known hypersensitivity or allergic reaction to any medication or hormone; strong
             allergic reaction to food.
          -  Infections such as COVID-19 or influenza, or unexplained fever.
          -  Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg).
          -  History of alcohol or drug abuse; smoker (≥ 10 cigarettes or ≥ 3 cigars or ≥ 3
             pipes/day); smoker using e-cigarettes.
          -  Blood donation (≤ 1 month prior to administration).
          -  Take oral contraceptives or receive hormonal medications in the three months prior to
             the experiment.
          -  Pregnant or breastfeeding.